The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.
about
Angiogenic factors in preeclampsia: potential for diagnosis and treatmentAngiogenic factors in diagnosis, management, and research in preeclampsia.Angiogenic factors and renal disease in pregnancy.Hematologic complications of pregnancy.Pre-eclampsia part 1: current understanding of its pathophysiology.Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy.New developments in the pathogenesis of preeclampsiaPlacental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.Angiogenic factors and preeclampsia.Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome.Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction.KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis.Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders.Angiogenic factors: Potential to change clinical practice in preeclampsia?Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia.
P2860
Q26825774-9E5E354E-ADC0-48A5-8FEA-CDD92102C8CCQ27692060-26520F73-7247-401B-BE83-D88D8793C884Q33401116-6779E8F8-4E09-4765-ADCC-12770A978FAEQ33409852-4E1A81AA-7646-4C30-AD8A-CA727D828F91Q33416340-B288C98E-F1CF-4C1C-BC1A-7CAF28DF3AFBQ33428073-DED0D59F-CD63-45E4-82A6-B9492B196710Q33826353-A9E08945-4D1B-41EB-9A0F-D1A9E85FD4B2Q33935675-CD40E158-0D53-4194-8E47-88772071FFADQ34500006-E94B90A0-8F8C-404A-8B98-10A88BE93A16Q34714082-20DA9858-9EEB-4DAE-8977-3C815FB07258Q35143007-0F85B3BD-207F-4790-9340-832CE7383B61Q37592279-CF1170E6-5B4A-47C0-9902-B09A657CE9EFQ38796954-A7D44CFB-A794-4DC2-BD4A-4DC0CC48B3E2Q39877275-FBA3A1B0-3E2F-45BF-AB03-0115D036ADA9Q44231405-3CC76A7A-2AA8-4FA9-AA90-86D6A0C2643CQ45835216-407F0484-F223-4A7E-9A57-5D3F71B9FE31Q46301113-4235BAD9-0045-490C-8CD8-60F86CBA9CF6Q52689980-D95B903A-1F55-4A63-867A-11DB0A3001FA
P2860
The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@ast
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@en
type
label
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@ast
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@en
prefLabel
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@ast
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@en
P2093
P2860
P1476
The use of angiogenic biomarke ...... cytopenia from HELLP syndrome.
@en
P2093
Brett Young
Kee-Hak Lim
Richard J Levine
Saira Salahuddin
Sarosh Rana
P2860
P304
P356
10.3109/14767050903184207
P577
2010-05-01T00:00:00Z